30 related articles for article (PubMed ID: 12765235)
1. Characterization of Batracylin-induced Renal and Bladder Toxicity in Rats.
Davis M; Bunin DI; Samuelsson SJ; Altera KP; Kinders RJ; Lawrence SM; Ji J; Ames MM; Buhrow SA; Walden C; Reid JM; Rausch LL; Parman T
Toxicol Pathol; 2015 Jun; 43(4):519-29. PubMed ID: 25274659
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcomes in rats given nephrocarcinogenic exposure to dietary ochratoxin a, followed by the tumour promoter sodium barbital for life: a pilot study.
Mantle PG; Dobrota M; Gillett CE; Odell EW; Pinder SE
Toxins (Basel); 2010 Apr; 2(4):552-71. PubMed ID: 22069599
[TBL] [Abstract][Full Text] [Related]
3. A review of the diagnosis and treatment of Ochratoxin A inhalational exposure associated with human illness and kidney disease including focal segmental glomerulosclerosis.
Hope JH; Hope BE
J Environ Public Health; 2012; 2012():835059. PubMed ID: 22253638
[TBL] [Abstract][Full Text] [Related]
4. Evidence for a role of oxidative stress in the carcinogenicity of ochratoxin a.
Marin-Kuan M; Ehrlich V; Delatour T; Cavin C; Schilter B
J Toxicol; 2011; 2011():645361. PubMed ID: 21776264
[TBL] [Abstract][Full Text] [Related]
5. Binding of ochratoxin A to a urinary globulin: a new concept to account for gender difference in rat nephrocarcinogenic responses.
Mantle PG; Nagy J
Int J Mol Sci; 2008 May; 9(5):719-735. PubMed ID: 19325780
[TBL] [Abstract][Full Text] [Related]
6. DNA adduct formation by ochratoxin A: review of the available evidence.
Mally A; Dekant W
Food Addit Contam; 2005; 22 Suppl 1():65-74. PubMed ID: 16332624
[TBL] [Abstract][Full Text] [Related]
7. Re: Comments on paper by Son et al.
Castegnaro M; Pfohl-Leszkowicz A; Bartsch H; Tillmann T; Mohr U
Toxicol Lett; 2005 Apr; 156(2):315; author reply 317. PubMed ID: 15737494
[No Abstract] [Full Text] [Related]
8. Strain-specific mammary proliferative lesion development following lifetime oral administration of ochratoxin A in DA and Lewis rats.
Son WC; Kamino K; Lee YS; Kang KS
Int J Cancer; 2003 Jun; 105(3):305-11. PubMed ID: 12704662
[TBL] [Abstract][Full Text] [Related]
9. Sex- and strain-specific induction of renal tumors by ochratoxin A in rats correlates with DNA adduction.
Castegnaro M; Mohr U; Pfohl-Leszkowicz A; Estève J; Steinmann J; Tillmann T; Michelon J; Bartsch H
Int J Cancer; 1998 Jul; 77(1):70-5. PubMed ID: 9639396
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of 2-mercaptoethane sulfonate and 6-phenylhexyl isothiocyanate on urinary bladder tumorigenesis in rats induced by N-butyl-N-(4-hydroxybutyl)nitrosamine.
Nishikawa A; Morse MA; Chung FL
Cancer Lett; 2003 Apr; 193(1):11-6. PubMed ID: 12691818
[TBL] [Abstract][Full Text] [Related]
11. Effect of the uroprotector sodium 2-mercaptoethane sulfonate (Mesna) on the proliferation of the bladder urothelium in the rat after administration of cyclophosphamide.
Kunze E; Köhnecke B; Engelhardt W; Steinröder H; Brock N; Pohl J
Urol Int; 1984; 39(2):61-7. PubMed ID: 6426112
[TBL] [Abstract][Full Text] [Related]
12. Lack of effects of sodium 2-mercaptoethane sulfonate (mesna) on Ochratoxin A induced renal tumorigenicity following life-time oral administration of Ochratoxin A in DA and Lewis rats.
Son WC; Kamino K; Lee YS; Kang KS
Toxicol Lett; 2003 Apr; 142(1-2):19-27. PubMed ID: 12765235
[TBL] [Abstract][Full Text] [Related]
13. Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.
Monach PA; Arnold LM; Merkel PA
Arthritis Rheum; 2010 Jan; 62(1):9-21. PubMed ID: 20039416
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
